Objective:

To assess whether glaucoma is associated with changes in sphingomyelin (SM), its metabolic enzymes, and ceramide in human retinal ganglion cells (RGCs).

Approach:

• Samples: Researchers examined fixed and flash-frozen retinal tissue from human donors with and without glaucoma.
• Measurements: They identified RGCs and assessed SM, acid and neutral sphingomyelinase (ASM and NSM), SM-synthesizing enzymes SMS1 and SMS2, and ceramide.

Key Findings:

• RGC density and SM labeling in surviving RGCs were significantly lower in glaucoma donor retinas; reduced SM was also confirmed in retinal homogenates.
• ASM expression was significantly higher in the RGC layer and within RGCs, while NSM, SMS1, and SMS2 showed no significant group differences.
• Total RGC ceramide levels did not differ significantly, but ceramide aggregates within RGCs were more abundant in glaucoma donor eyes.

Interpretation:

The authors suggest that increased ASM-mediated SM breakdown may contribute to SM depletion and localized ceramide aggregation in glaucomatous RGCs. They propose that ceramide-rich membrane platforms could amplify pro-apoptotic signaling.

Limitations:

• The number of human donor samples was small, and medical histories were incomplete.
• Causes of death were not balanced between groups; sepsis was more common among glaucoma donors and may be a confounder.

Conclusion:

The study provides human donor evidence of disruption in the ASM–SM–ceramide pathway in glaucoma. The authors note that, alongside earlier animal findings, the results raise ASM inhibition as a possible future neuroprotective strategy.

Sources:

• Article context provided by the user